TORONTO, Nov. 21, 2019 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America, today announced
that Company Director and 55th President of Mexico, Vicente
Fox, will present a keynote address at the Bryan, Garnier
& Co Cannabis Conference, taking place on Thursday, November 28, 2019 in London, UK.
Hosted at The May Fair, the conference will bring together
global leaders in the cannabis sector, with presentations and panel
discussions on the future of medical cannabis in Europe and the developing market for
recreational and wellness cannabis brands.
Pres. Fox will present a keynote address at the conference,
discussing the industry view from Latin
America, the market opportunity for cannabis in Europe, and Khiron's focused strategy in these
markets. Tejinder Virk, President,
Khiron Europe, and Franziska Katterbach, Chief Legal Officer,
Khiron Europe, will also present at the conference and will be
available for one-on-one meetings which can be scheduled at
investors@khiron.ca
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full-service
growth-focused independent investment banking partnership founded
in 1996. The firm provides equity research, sales and trading,
private and public capital raising as well as M&A services to
growth companies and their investors. It focuses on key growth
sectors of the economy including Technology, Healthcare, Consumer
and Business Services. Bryan, Garnier & Co is a fully
registered broker dealer authorized and regulated by the FCA in
Europe and the FINRA in the U.S.
Bryan, Garnier & Co is headquartered in London, with additional offices in
Paris, Munich, Stockholm, Oslo, Reykjavik as well as New York and Palo
Alto. The firm is a member of the London Stock
Exchange.
To register, please visit the conference webpage, journalists
are welcome: http://cannabisconference2019.evenium-site.com/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found at
www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-director-and-55th-president-of-mexico-vicente-fox-to-present-keynote-at-uk-cannabis-investor-conference-300962565.html
SOURCE Khiron Life Sciences Corp.